Experienced life science entrepreneur & executive. Successful deals and financings (e.g., J&J, Novartis, Santen, Novartis Ventures, ATEL Ventures). Director, Avaolon GloboCare Corp. Previously, CEO at Adial Pharmaceuticals, VP Bus Dev & Strategic Projects at Clinical Data. COO & CFO Adenosine Therapeutics. Captain, U.S. Marine Corps. Darden MBA.

Co-founder & CEO of Purnovate until acquisition by Adial. Over 35 years experience in medicinal chemistry focused primarily on adenosine analogs. Acknowledged world leader in adenosine chemistry. Inventor of over 20 issued patents. Leader in multiple biotech companies successfully sold.

Mr. Gupta is an experienced entrepreneur and executive with over a 20-year record of accomplishments commercializing novel innovations in many segments across healthcare. Prior experience includes launching products in drug discovery/regenerative medicine, functional food ingredients and medical devices. He also spent time in a Fortune 100 company where he delivered critical financial results by leading the launch and oversight of new solutions.

Dr. Linden has been at the forefront of adenosine research and breakthroughs for over 40 years. His UVA laboratory was the first to study cardiac and vascular adenosine receptors by developing novel radioligands. He has 34 issued US patents, published over 300 papers and been cited over 30,000 times (top 2% world-wide). His discoveries in immuno-modulatory effects of adenosine receptors were the basis for Adenosine Therapeutics.